Sweden wants to link drug approval to environmental risk assessment
This article was originally published in SRA
The Swedish Medical Products Agency is proposing that approval of human medicines in the European Union should require an environmental risk assessment of the production facilities where the products are manufactured and that marketing authorisation should be denied if any risk of negative environmental effects is found1.
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.